Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
0(0%)
Results Posted
71%(5 trials)

Phase Distribution

Ph phase_1
2
29%
Ph phase_2
5
71%

Phase Distribution

2

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
5(71.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(7)

Detailed Status

Completed7

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (28.6%)
Phase 25 (71.4%)

Trials by Status

completed7100%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_2

Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly

NCT03312231
completedphase_2

2013/2017 H7N9 Prime-Boost Interval

NCT03589807
completedphase_2

2017 A/H7N9 IIV Revaccination

NCT03738241
completedphase_2

Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

NCT03682120
completedphase_2

Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

NCT03318315
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT03312231Phase 2

Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly

Completed
NCT03589807Phase 2

2013/2017 H7N9 Prime-Boost Interval

Completed
NCT03738241Phase 2

2017 A/H7N9 IIV Revaccination

Completed
NCT03682120Phase 2

Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

Completed
NCT03318315Phase 2

Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

Completed
NCT01317745Phase 1

H5N1 Mix and Match With MF59

Completed
NCT01317758Phase 1

H5N1 Mix and Match With AS03

Completed

All 7 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
7